Wednesday, July 8, 2026

Patent intelligence · US

US 7390815

Pyrazole compounds useful as protein kinase inhibitors

granted A61PA61P1/16A61P11/06A61P17/06
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 2
Applicant portfolio 991
Patent details — US 7390815
Jurisdiction
US
Status
granted
Grant date
Jun 24, 2008
Expiration
Jun 19, 2028
Claims
17
CPC classes
A61P, A61P1/16, A61P11/06, A61P17/06
View on Google Patents ↗

Quick answer

US 7390815 (Pyrazole compounds useful as protein kinase inhibitors) is held by Vertex Pharmaceuticals Incorporated. Status: granted. Granted Jun 24, 2008. Expires Jun 19, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
17
CPC classes
A61P, A61P1/16, A61P11/06, A61P17/06, A61P19/00, A61P19/02

More from Vertex Pharmaceuticals Incorporated

Related pharmaceutical patents in our USPTO index.

  1. US 12421251

    Cystic fibrosis transmembrane conductance regulator modulating agents

    Vertex Pharmaceuticals Incorporated · Expires Sep 18, 2045

    granted
  2. US 12421249

    Inhibitors of APOL1 and methods of using same

    Vertex Pharmaceuticals Incorporated · Expires Sep 18, 2045

    granted
  3. US 12384790

    Pteridinone compounds and uses thereof

    Vertex Pharmaceuticals Incorporated · Expires Aug 7, 2045

    granted
  4. US 12384762

    Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Vertex Pharmaceuticals Incorporated · Expires Aug 7, 2045

    granted
  5. US 12385013

    Differentiation of pancreatic endocrine cells

    Vertex Pharmaceuticals Incorporated · Expires Aug 7, 2045

    granted
  6. US 12377252

    Implantation devices, system, and methods

    Vertex Pharmaceuticals Incorporated · Expires Jul 31, 2045

    granted
  7. US 12371665

    Differentiation of pancreatic endocrine cells

    Vertex Pharmaceuticals Incorporated · Expires Jul 24, 2045

    granted
  8. US 12350262

    Methods of treatment for cystic fibrosis

    Vertex Pharmaceuticals Incorporated · Expires Jul 3, 2045

    granted

Frequently asked questions

What is US patent 7390815?

US 7390815 (Pyrazole compounds useful as protein kinase inhibitors) is held by Vertex Pharmaceuticals Incorporated. Status: granted. Granted Jun 24, 2008. Expires Jun 19, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 7390815?

Vertex Pharmaceuticals Incorporated is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 991 pharmaceutical patents for this assignee.

When does US 7390815 expire?

Our index shows an expiration date of Jun 19, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.